Frequently Asked Questions
The market is segmented based on Global Preimplantation Genetic Screening (PGS) Technology Market, By Procedure Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), Product and Services (Reagents and Consumables, Instruments, Software and Services), End User (Maternity Centers and Fertility Clinics, Hospitals, Diagnostic Labs, and Service Providers, Research Laboratories and Academic Institutes), Test Type (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, Other PGT Types), Application (Embryo HLA Typing for Stem Cell Therapy, IVF Prognosis, Late Onset Genetic Disorders, Inherited Genetic Disease, Others) – Industry Trends and Forecast to 2029
.
The Global Preimplantation Genetic Screening Pgs Technology Market size was valued at USD 552.50 USD Million in 2021.
The Global Preimplantation Genetic Screening Pgs Technology Market is projected to grow at a CAGR of 10.5% during the forecast period of 2022 to 2029.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
